StockWatch
·
MARKSANS PHARMA LTD. · QQ2 FY-2027 · THE CALL

Record growth beats guidance, but QoQ PAT decline flags cost pressure

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsMARKSANSMARKSANS PHARMA LTD.13 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

Beat FY27 revenue guide (30.5% vs 15-20%), margin guide met (22.8% vs 20-21% sustainable). Sequential PAT decline signals first cost-management miss.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Strong revenue momentum (30.5% YoY) validates diversification strategy, but Q2 PAT fell 10% QoQ despite revenue growth—freight ₹20Cr, acquisition depreciation ₹6-7Cr, labour ₹8Cr pressured margins. European M&A and U.S. order book 3-year targets credible, but execution risk and near-term cost headwinds warrant caution.

₹940.2 Cr

Revenue · +30.5% YoY

₹143.5 Cr

Reported PAT · +44.8% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Record Q2 revenue INR940 Cr, YoY growth 30.5%

MET

Delivered ₹940.2 Cr, +30.5% YoY. Matches reported.

EBITDA ₹214 Cr, margin 22.8%, up 274 bps YoY

MET

EBITDA margin 22.8% confirmed; growth rate consistent with strong Q2 performance.

PAT ₹144 Cr, up 44.8% YoY

MET

Delivered ₹143.5 Cr, +44.8% YoY. Matches.

North America ₹421 Cr (45% revenue), Europe ₹405 Cr (43%)

MET

Geographic split confirmed; Europe +65% YoY vastly exceeds prior ₹180 Cr FY target.

Europe positioned as key long-term driver; 3-year ₹1,000 Cr+ objective

MET

Currently ₹405 Cr H1 run rate. On track; M&A (QlinIQ, ABCnow, GmbH) provides infrastructure.

Earnings quality

What changed since the last call

Deltas vs. the prior call

European expansion materially accelerated

Upgrade

Prior ₹180Cr FY target now exceeded (₹405Cr H1). Three M&A deals (QlinIQ, ABCnow, GmbH) now active. 3-year visibility on Europe.

U.S. order book target quantified

New

$225M→$300M over 3 years (explicit). Prior vague bullishness now concrete milestone.

India capacity roadmap formalized

New

16B units/year oral solid target; plant acquisition dialogue active, 12-18m timeline.

EBITDA margin guidance reaffirmed at 21%-22%

Neutral

Running 22.8% in Q2, 24% in H1; expect normalization to 21%-22% as freight stabilizes, depreciation absorbs.

The Q&A

Analysts pressed U.S. seasonality, margin ceiling (deflected), capex timing, API costs. Management direct on most; avoided margin upside speculation. Q&A thorough but contained several partial dodges on specific M&A timelines, dividend policy.

The exchanges that mattered

U.S. growth and market outlook — Ahmed Madha, Unifi Capital

Answered

Seasonality key (Q3/Q4 stronger). Order book healthy. Price erosion single digits. Within 3 years target $300M order book from ~$225M.

Europe growth trajectory — Arun, Unifi Capital

Partial

New product launches, pipeline approvals underway. Growth over couple of years to hit ₹6,000Cr objective. No specific ₹X guidance.

Capex and capacity expansion — Saksham Tyagi, Desvelado Advisory

Partial

Two-phase: internal debottleneck + acquire facility (12-18m impact lag). Dialogue with 2 companies, nothing concrete yet.

Manufacturing assets and dosage forms — Mihir Damania, Fident AMC

Answered

Expanding dosage forms (not injectables). Oral remains core. 2-year horizon for new form scaling. No API backward integration.

Depreciation accounting change — Mihir Damania, Fident AMC

Answered

Changed intangible asset treatment Q2 (indefinite→finite 10-year life). QlinIQ, ABCnow amortization starting. Expect similar run rate next 2 quarters.

U.S. OTC channel strategy — Akshit Shetty, Manjit Kothari Family Office

Answered

Already positioned with retailers; dialogues on innovation/launches. Some retailers seeking innovation direction from us.

European M&A and product introduction — Akshit Shetty, Manjit Kothari Family Office

Partial

QlinIQ (Netherlands), ABCnow (Germany) deals live. Each market differs. Both add tangible and intangible growth. More M&A likely in next 12m.

Australia growth and Nova subsidiary — Pranav Gupta, Value Advisors

Answered

100% of Australia via Nova. Scaling to $100M subsidiary over 3 years. Nova is front-end, not manufacturing.

Revenue run-rate targets and capex cycle — Tanvi, Mira Capital

Answered

Trending near INR1,000Cr/quarter; next year should touch INR4,000Cr run rate. Capex coming for manufacturing to hit INR5,000Cr+ target.

API cost pressures and gross margin outlook — Arun, Unifi Capital (repeat)

Answered

Expect 21%-22% EBITDA going forward. If crude eases, margin upside. If crude up, headwind. Retailers won't accept price increases.

Margin ceiling and upside scenario — Harshali, ASK Wealth Advisors

Dodged

Always a possibility, but for that you've got to call the president and call off the war. 21%-22% range expected.

R&D focus and competitive positioning — Vishal Manchanda, Systematix Institutional Equities

Answered

Niche oral solids where competition is lower. No injectables. Competitors facing same cost pressures. Growth from volume, geography, mix—not pricing power.

Organic vs inorganic growth split — Vishal Manchanda, Systematix Institutional Equities

Answered

U.K. 20% new launches. Europe 50%-60% new launches. U.S. 10%. Geographic diversification is bigger driver.

Lease liability increase and U.K. expansion — Arun, Unifi Capital (repeat)

Answered

New lease in U.K. from geographic expansion. Consolidation ongoing.

Guidance

Forward guidance and management's confidence

FY27 revenue growth 15-20% reaffirmed

High

Tracking +30.5% YoY; guidance conservative. H2 seasonality favorable, but geopolitical headwinds may moderate.

INR4,000Cr annual run rate achievable next year

High

Currently INR1,000Cr/quarter; organic growth + Europe contribution support.

U.S. order book $225M→$300M over 3 years

High

Explicit target; price erosion single digits; multiple ANDAs in pipeline.

EBITDA margin 21%-22% range going forward

High

Currently 22.8% Q2, 24% H1; expect mean reversion as freight, depreciation stabilize.

Gross margin normalize to 55%-56% (prior guidance)

Medium

Currently 58.5%, above target. Q1 inventory benefit, Q2 freight headwind. Volatility expected Q3/Q4.

Indian manufacturing acquisition/expansion in 12-18 months

Medium

Dialogue active; major capex required for ₹5,000-6,000Cr revenue targets.

Risks the call surfaced

Ranked by how much they should concern a holder

Geopolitical supply chain disruption

Medium

Red Sea shipping delays affecting Middle East and ROW markets. Q2 shipment timing impacted; expected recovery by FY27 end.

Input cost inflation

Medium

Paracetamol, ibuprofen APIs at elevated levels. Freight up ₹20Cr Q2. Retailers resisting price increases.

U.S. price erosion

Medium

Single-digit price erosion ongoing in U.S. OTC market. Geopolitical uncertainty moderating consumer sentiment.

M&A integration execution

Medium

QlinIQ, ABCnow ramping; future Indian plant acquisition pending. Integration delays could impact revenue/margin targets.

Management

Score 7/10. Direct on financials, conservative on timelines (Europe 3-year, M&A 12-18m). Deflected margin upside question. Mostly transparent on cost headwinds. Beat FY27 revenue guidance (30.5% vs 15-20%). EBITDA margin met (22.8% vs 20-21%). Sequential PAT decline not frontally addressed; signal of margin pressure.

What to watch next
  • 1 · Q3 FY27

    Seasonally stronger quarter; winter cold-season demand peak

  • 2 · Next 12m

    5-6 ANDA approvals expected; European M&A integration (QlinIQ, ABCnow ramp)

  • 3 · Next 12-18m

    Indian manufacturing asset acquisition; 16B units/year capacity target

order book 3-year targets credible, but execution risk and near-term cost headwinds warrant caution.

Informational and educational content only. Not investment advice.